Overview

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Hoffmann-La Roche
Treatments:
Antibodies, Monoclonal
Atezolizumab
Bevacizumab